Discovery of Pyrroloaminopyrazoles as Novel Pak Inhibitors.
Guo, C., Mcalpine, I., Zhang, J., Knighton, D.D., Kephart, S., Johnson, M.C., Li, H., Bouzida, D., Yang, A., Dong, L., Marakovits, J., Tikhe, J., Richardson, P., Guo, L.C., Kania, R., Edwards, M.P., Kraynov, E., Christensen, J., Piraino, J., Lee, J., Dagostino, E., Del-Carmen, C., Deng, Y.L., Smeal, T., Murray, B.W.(2012) J Med Chem 55: 4728
- PubMed: 22554206 
- DOI: https://doi.org/10.1021/jm300204j
- Primary Citation of Related Structures:  
4APP - PubMed Abstract: 
The P21-activated kinases (PAK) are emerging antitumor therapeutic targets. In this paper, we describe the discovery of potent PAK inhibitors guided by structure-based drug design. In addition, the efflux of the pyrrolopyrazole series was effectively reduced by applying multiple medicinal chemistry strategies, leading to a series of PAK inhibitors that are orally active in inhibiting tumor growth in vivo.
Organizational Affiliation: 
Pfizer Global Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States. alexguo01@gmail.com